Literature DB >> 15302162

Electron microscopic and immunochemical analysis of the broadly neutralizing HIV-1-specific, anti-carbohydrate antibody, 2G12.

K H Roux1, Ping Zhu, Margaret Seavy, Hermann Katinger, Renate Kunert, Vanessa Seamon.   

Abstract

2G12 is one of only a few cloned antibodies with broadly neutralizing specificity to HIV-1 envelope proteins. Crystallographic and electron microscopic (EM) data showed that the Fab arms are locked together via a novel VH domain exchange. Both the conventional and the unprecedented additional VH-VH antigen binding sites show specificity for high mannose oligosaccharides on the silent face of gp120. We have now extended the EM and biochemical analysis of 2G12. Unligated 2G12 IgG1 molecules clearly show paired (parallel attached) Fab arms in the "doughnut" configuration attached to the Fc both in individual and computationally averaged images. A minority of the IgG molecules in the 2G12 prep showed the open "Y" configuration of conventional IgG. The averaged EM image compares well to the atomic structure model of 2G12. Papain digests of 2G12 yielded paired Fab arms (Fab dimer), as observed by EM, which dissociated into Fab-sized fragments in non-reducing SDS-PAGE. Purified 2G12 reduced and alkylated H and L chains can reassociate to form IgG molecules with the Fab dimer configuration and can combine with L and H chains from conventional human IgG to form hybrid molecules. 2G12 is heavily aggregated following brief acid exposure possibly as a result of its unique structure. A model of the aggregation process is proposed. An anti-Id MAb was shown by EM to react with neither the conventional nor additional antigen binding sites, but bound to the lateral faces of the Fab arms of intact, reduced and alkylated, and reconstructed 2G12 molecules. Efforts to identify IgG molecules with a similar intertwined Fab dimer structure in a large IgG pool were unsuccessful.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302162     DOI: 10.1016/j.molimm.2004.05.008

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  12 in total

1.  Very few substitutions in a germ line antibody are required to initiate significant domain exchange.

Authors:  Michael Huber; Khoa M Le; Katie J Doores; Zara Fulton; Robyn L Stanfield; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

2.  Global shape and ligand binding efficiency of the HIV-1-neutralizing antibodies differ from those of antibodies that cannot neutralize HIV-1.

Authors:  Ashish K Solanki; Yogendra S Rathore; Maulik D Badmalia; Reema R Dhoke; Samir K Nath; Deepak Nihalani
Journal:  J Biol Chem       Date:  2014-10-20       Impact factor: 5.157

3.  Evidence for intermolecular domain exchange in the Fab domains of dimer and oligomers of an IgG1 monoclonal antibody.

Authors:  Yin Luo; Stephen W Raso; Judith Gallant; Colleen Steinmeyer; Yasuko Mabuchi; Zhaojiang Lu; Clifford Entrican; Jason C Rouse
Journal:  MAbs       Date:  2017-06-07       Impact factor: 5.857

4.  A strategy for phage display selection of functional domain-exchanged immunoglobulin scaffolds with high affinity for glycan targets.

Authors:  Alex Stewart; Yanyun Liu; Jonathan R Lai
Journal:  J Immunol Methods       Date:  2011-12-31       Impact factor: 2.303

5.  2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies.

Authors:  Katie J Doores; Michael Huber; Khoa M Le; Sheng-Kai Wang; Colleen Doyle-Cooper; Anthony Cooper; Ralph Pantophlet; Chi-Huey Wong; David Nemazee; Dennis R Burton
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

6.  Proline is not uniquely capable of providing the pivot point for domain swapping in 2G12, a broadly neutralizing antibody against HIV-1.

Authors:  Johannes S Gach; Paul G Furtmüller; Heribert Quendler; Paul Messner; Ralf Wagner; Hermann Katinger; Renate Kunert
Journal:  J Biol Chem       Date:  2009-11-10       Impact factor: 5.157

7.  Design and expression of a dimeric form of human immunodeficiency virus type 1 antibody 2G12 with increased neutralization potency.

Authors:  Anthony P West; Rachel P Galimidi; Christopher P Foglesong; Priyanthi N P Gnanapragasam; Kathryn E Huey-Tubman; Joshua S Klein; Maria D Suzuki; Noreen E Tiangco; Jost Vielmetter; Pamela J Bjorkman
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

8.  A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120.

Authors:  Alfredo Menendez; Daniel A Calarese; Robyn L Stanfield; Keith C Chow; Chris N Scanlan; Renate Kunert; Herman Katinger; Dennis R Burton; Ian A Wilson; Jamie K Scott
Journal:  FASEB J       Date:  2008-01-15       Impact factor: 5.191

9.  Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Authors:  Ann J Hessell; Eva G Rakasz; Pascal Poignard; Lars Hangartner; Gary Landucci; Donald N Forthal; Wayne C Koff; David I Watkins; Dennis R Burton
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

10.  Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120.

Authors:  Hongying Chen; Xiaodong Xu; Hsin-Hui Lin; Ssu-Hsien Chen; Anna Forsman; Marlen Aasa-Chapman; Ian M Jones
Journal:  J Gen Virol       Date:  2008-10       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.